Transthyretin Amyloidosis with Cardiomyopathy
📧 Sign up to get email alerts when something new happens for Transthyretin Amyloidosis with Cardiomyopathy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-17FDA Approved: VYNDAMAX — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for VYNDAMAX (tafamidis) from Pfizer Laboratories Div Pfizer Inc, typically to support labeling …
-
FDA approval · 2019-05-03FDA Approved: VYNDAMAX — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved the original application for VYNDAMAX (TAFAMIDIS) from Pfizer Laboratories Div Pfizer Inc for the treatment of transthyretin am…